Tier 4 — mechanistic

Betaine Inhibits Interleukin-1β Production and Release: Potential Mechanisms

Yaoyao Xia, Shuai Chen, Guoqiang Zhu, Ruilin Huang, Yulong Yin, Wenkai Ren
Frontiers in immunology 2018 9:2670

Bibliography

PubMed
PMID 30515160
PubMed Central
PMC6255979
DOI
10.3389/fimmu.2018.02670
Funding
Reported funding/support: National Natural Science Foundation of China10.13039/50110000180931790411National Key R&D Program of China2018YFD0500600Natural Science Foundation of Guangdong Province10.13039/5011000034532017A0303104102017A030310398
Competing interests
Reported disclosure: statementThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Study snapshot

DesignNarrative review
ModelEvidence synthesis; mixed research models
SamplePublished literature; no newly enrolled participant cohort
InterventionReview of betaine-related evidence; no single assigned intervention
DurationEvidence review; source-specific study durations vary
EndpointsBetaine biology; Clinical and mechanistic evidence

What the study showed, in plain terms

Published in 2018, this source examined mechanistic and clinical reviews. Its evidence base was Published literature; no newly enrolled participant cohort. It evaluated Review of betaine-related evidence; no single assigned intervention across Evidence review; source-specific study durations vary.

Explains proposed routes by which betaine could affect IL-1beta production, processing and release.

A mechanistic review rather than a clinical efficacy trial; pathway effects are not proof of symptom or disease improvement.

Continue with TMG Data Center

Continue with TMG Supplement: Trimethylglycine Benefits, Uses and Evidence

Key findings

  • Explains proposed routes by which betaine could affect IL-1beta production, processing and release.
  • The recorded outcome domains were Betaine biology; Clinical and mechanistic evidence.

What this study can and cannot tell us

  • A mechanistic review rather than a clinical efficacy trial; pathway effects are not proof of symptom or disease improvement.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Accessible full-text extract plus indexed bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Decoding Betaine: A Critical Analysis of Therapeutic Potential Compared with Marketing Hype-A Narrative Review
Grzegorz Nikrandt et al. · The Journal of nutrition · 2024
Tier 4
Beneficial Effects of Betaine: A Comprehensive Review
Madan Kumar Arumugam et al. · Biology · 2021
Tier 4
Betaine in human nutrition
Stuart A S Craig et al. · The American journal of clinical nutrition · 2004
Tier 4
Choline and betaine in health and disease
Per Magne Ueland et al. · Journal of inherited metabolic disease · 2011

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology